Premium
Effects of UP 614‐04, a potential antidepressant, on cerebral monoamine oxidase activity
Author(s) -
Cloarec Alix,
Chevalier Ghislaine,
Delchambre Chantal,
Tremblay Dominique
Publication year - 1983
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430030207
Subject(s) - pargyline , monoamine oxidase , antidepressant , pharmacology , ex vivo , chemistry , in vivo , monoamine neurotransmitter , monoamine oxidase b , in vitro , biochemistry , serotonin , endocrinology , medicine , biology , enzyme , receptor , hippocampus , microbiology and biotechnology
The effects of UP 614‐04, a potential antidepressant agent, and those of some known antidepressant agents on cerebral monoamine oxidase (MAO) activity were compared in rats and mice. Using ex vivo and in vitro techniques, it was shown that UP 614‐04, a viloxazine analogue, inhibited cerebral MAO activity in rats and mice ex vivo, but that it was not effective in vitro. Time‐course studies revealed that the action of UP 614‐04 was more sustained than that of viloxazine, but much less potent or sustained than those of pargyline or isocarboxazide. The effect of UP 614‐04 was not selective to the A or B forms of MAO.